UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036956
Receipt number R000042104
Scientific Title A tau PET study with 18F-THK5351 on neurodegenerative disorders patients.
Date of disclosure of the study information 2019/06/04
Last modified on 2019/12/04 10:29:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A tau PET study with 18F-THK5351 on neurodegenerative disorders patients.

Acronym

A tau PET study with 18F-THK5351 on neurodegenerative disorders patients.

Scientific Title

A tau PET study with 18F-THK5351 on neurodegenerative disorders patients.

Scientific Title:Acronym

A tau PET study with 18F-THK5351 on neurodegenerative disorders patients.

Region

Japan


Condition

Condition

Patients who are suspected neurodegenerative disorders including Alzheimer disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, frontotemporal lobe degeneration, Parkinson's disease, dementia with Lewy bodies, and others including possibly tau positive, negative, and inconstant disorders.

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To disclose heterogeneity of tau and amyloid deposit among brains of various neurodegenerative disorders patients by using 18F-THK5351 and 11C-PiB PET.

Basic objectives2

Others

Basic objectives -Others

pathophysiology

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Comparison of the distribution of tau deposit among disorders manifesting parkinsonism or dementia.

Key secondary outcomes

Relationship between clinical pictures and distributions of tau and amyloid deposit.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

18F-THK5351 and 11C-PiB PET

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who have intention to participate in the PET study and are suspected having neurodegenerative disorders.

Key exclusion criteria

Patients having history of seizure, alcoholism, or any kind of drug dependency.
Patients recognized to be inappropriate by anyone of attending physicians or study staffs.

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Yoshihiko
Middle name
Last name Horimoto

Organization

Nagoya City Rehabilitation Agency

Division name

Department of Neurology

Zip code

4678622

Address

1-2 Mikanyama, Yatomi-cho, Mizuho-ku, Nagoya, Japan

TEL

052-835-3811

Email

holly@nagoya-rehab.or.jp


Public contact

Name of contact person

1st name Yoshihiko
Middle name
Last name Horimoto

Organization

Nagoya City Rehabilitation Agency

Division name

Department of Neurology

Zip code

4678622

Address

1-2 Mikanyama, Yatomi-cho, Mizuho-ku, Nagoya, Japan

TEL

052-835-3811

Homepage URL


Email

holly@nagoya-rehab.or.jp


Sponsor or person

Institute

Nagoya City Rehabilitation Agency

Institute

Department

Personal name



Funding Source

Organization

Nagoya City Rehabilitation Agency

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya City Rehabilitation Agency

Address

1-2 Mikanyama, Yatomi-cho, Mizuho-ku, Nagoya, Japan

Tel

052-835-3811

Email

soumubu@nagoya-rehab.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

名古屋市総合リハビリテーション事業団(愛知県)


Other administrative information

Date of disclosure of the study information

2019 Year 06 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2019 Year 06 Month 10 Day

Date of IRB

2019 Year 04 Month 19 Day

Anticipated trial start date

2019 Year 06 Month 11 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 06 Month 04 Day

Last modified on

2019 Year 12 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042104


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name